DRGT Announces First Subject Dosed in a Phase I Clinical Trial of DRGT 45, a Novel Formulation of Abiraterone Acetate for Prostate Cancer
29. Oktober 2019 09:00 ET
|
Druggability Technologies Holdings Ltd
BUDAPEST, Hungary, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Druggability Technologies Holdings (DRGT) today announces the first subject dosed in a two-part Phase I trial to evaluate the pharmacokinetics,...